Management of High‑Risk Soft‑Tissue Sarcoma

Definition of High‑Risk Disease

High‑risk soft‑tissue sarcomas are defined by histologic grade G2‑3, deep location relative to the fascia, and a maximum diameter > 5 cm. 1

Wide excision performed by an experienced sarcoma surgeon, aiming for at least a 1‑cm circumferential margin of normal tissue when feasible, is the cornerstone of curative treatment. 1
For intracompartimental tumors that can be removed with compartmental resection, adjuvant radiotherapy is not required. 1
If microscopic positive margins (R1) are present, re‑excision should be considered provided adequate margins can be obtained without substantial additional morbidity. 1
If macroscopic positive margins (R2) are present, re‑excision is mandatory; neoadjuvant therapy may be employed when clear margins cannot be achieved surgically. 1

Post‑operative external‑beam radiotherapy is recommended at a total dose of 50–60 Gy delivered in 1.8–2 Gy fractions, with a possible boost up to 66 Gy based on surgical quality and tumor presentation. 1
Radiotherapy improves local control but does not translate into an overall‑survival benefit. 2
Pre‑operative radiotherapy (standard 50 Gy in 25 fractions) can shrink tumors and facilitate surgery, but it is associated with higher acute wound‑healing complications and lower late toxicity compared with postoperative treatment. 2

Adjuvant chemotherapy is not a standard of care for high‑risk soft‑tissue sarcoma; it may be offered to selected high‑risk patients after shared decision‑making. 3
A meta‑analysis of randomized trials demonstrated a statistically significant but modest improvement in overall survival and disease‑free survival with adjuvant chemotherapy. 3
Evidence is conflicting, and no definitive efficacy has been established across all studies. 1
Histologic subtype should guide chemotherapy decisions; chemosensitive subtypes may benefit, whereas known chemo‑resistant histologies should not receive systemic chemotherapy. 1 (chemosensitive) / 3 (chemo‑resistant)
When chemotherapy is chosen as part of initial treatment, a pre‑operative component can be administered. 1

Adding regional hyperthermia to systemic chemotherapy provides a significant advantage in local control and disease‑free survival for high‑risk patients (G2‑3, deep, >5 cm). 3
A large phase‑III randomized trial confirmed this benefit in the same patient population. 3
Regional hyperthermia is especially indicated for tumors that are unresectable or would otherwise require mutilating surgery. 4
Hyperthermia‑related toxicities are generally mild to moderate, most commonly pain, pressure discomfort, and superficial skin burns. 4

Regional nodal metastases occur in approximately 4 % of soft‑tissue sarcoma cases and represent an adverse prognostic factor that warrants aggressive multimodal therapy. 5
Treatment should include wide excision of both the primary tumor and involved nodes, combined with adjuvant radiotherapy and chemotherapy for chemosensitive histologies. 5
Because nodal involvement implies systemic disease, these modalities are not truly “adjuvant” but part of definitive therapy. 3
Mutilating surgery should be avoided in this setting. 5
Isolated limb perfusion with TNF‑α + melphalan is an option for limb‑confined disease, often combined with systemic chemotherapy and radiotherapy. 3

Extensive lymph‑node dissection for clinically negative nodes (cN0) provides no survival benefit and should be omitted. 5
Patients with nodal metastases must not be managed as if they have purely adjuvant disease; the presence of nodal spread indicates systemic involvement with a poorer prognosis. 5
Radiotherapy should be administered after marginal, R1, or R2 resections when re‑excision is not feasible, even if this falls outside typical indications. 1

All cases require mandatory multidisciplinary treatment planning involving pathologists, radiologists, sarcoma surgeons, radiation oncologists, and medical oncologists, and should be conducted in dedicated sarcoma reference centers. 1

Radiation therapy is the established standard treatment for high‑risk synovial sarcoma after complete resection, and should be administered to all patients meeting high‑risk criteria (size ≥ 5 cm, deep location, positive/close margins, or high‑grade histology)【6】.

Although adjuvant chemotherapy is not routine for adult soft‑tissue sarcomas overall, synovial sarcoma is an exception owing to its documented chemosensitivity; therefore, systemic therapy should be strongly considered for high‑risk cases【6】【7】.
The recommended adjuvant regimen is an anthracycline (doxorubicin) combined with ifosfamide, delivered in 3–4 cycles every 3 weeks, with dose monitoring to limit cardiotoxicity【6】【7】.
General soft‑tissue sarcoma meta‑analyses demonstrate only a modest but statistically significant overall‑survival benefit from adjuvant chemotherapy (Level II evidence)【6】.
The EORTC‑62931 phase‑III trial found no overall‑survival advantage for adjuvant doxorubicin + ifosfamide in an unselected population of high‑grade sarcomas (Level I evidence)【7】.
Importantly, neither the meta‑analyses nor the EORTC‑62931 trial specifically evaluated synovial sarcoma as a distinct, chemosensitive subtype【6】【7】.
After multidisciplinary discussion and shared decision‑making, adjuvant chemotherapy should be offered to patients with high‑risk synovial sarcoma (strong recommendation)【6】.

Pre‑operative (neoadjuvant) chemotherapy may be employed to assess tumor response and facilitate subsequent surgical resection【6】.
Radiation therapy should be scheduled so that it does not delay the initiation of chemotherapy, preserving timely systemic treatment of micrometastatic disease【6】.
When both modalities are administered post‑operatively, either can be started first; however, initiating chemotherapy promptly is preferred to address potential micrometastases【6】.

Radiotherapy must not be omitted in high‑risk synovial sarcoma, as it is the only modality proven to improve local control【6】.
Synovial sarcoma should not be grouped with chemotherapy‑resistant sarcoma subtypes; its inherent chemosensitivity justifies the use of systemic therapy【6】.
Treatment should be delivered at a specialized sarcoma center with expertise in multidisciplinary care, including pathology confirmation, surgical oncology, radiation oncology, and medical oncology【6】.